Testing a new antibody drug for advanced cancers
What is this trial?
This trial tested a new drug called TQB2210, which is a type of antibody designed to fight certain advanced cancers by blocking a specific protein that helps tumors grow. Researchers studied how well patients tolerated the drug, how their bodies processed it, and whether it helped slow or shrink their tumors. The trial focused on patients whose cancers had a particular genetic feature and had not responded to standard treatments.
Many patients with advanced cancers like gastric cancer run out of effective treatment options. This trial was designed to see if this new antibody drug could offer hope to those patients by targeting a specific weakness in their cancer cells.
What participation looks like
Participants received intravenous infusions of TQB2210 once every two weeks, with each 4-week period counting as one treatment cycle. The trial started with lower doses and gradually increased them to find the safest and most effective dose. Participants underwent regular blood tests, imaging scans to measure their tumors, and check-ins with the research team to monitor how they were responding and whether they experienced any side effects.
AI-generated summary from trial data · Apr 17, 2026 · Not medical advice
Trial locations(7 sites)
China